Haleon PLC Sponsored ADR (NYSE:HLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company.

A number of analysts have commented on the company. Argus upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Finally, Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st.

Hedge Funds Weigh In On Haleon

Several large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC lifted its position in Haleon by 20.4% during the first quarter. Parallel Advisors LLC now owns 30,272 shares of the company’s stock worth $303,000 after buying an additional 5,134 shares during the period. Allen Capital Group LLC lifted its position in Haleon by 14.5% during the first quarter. Allen Capital Group LLC now owns 13,628 shares of the company’s stock worth $136,000 after buying an additional 1,729 shares during the period. Summitry LLC lifted its position in Haleon by 4.2% during the first quarter. Summitry LLC now owns 52,951 shares of the company’s stock worth $530,000 after buying an additional 2,136 shares during the period. Western Wealth Management LLC purchased a new position in Haleon during the first quarter worth about $29,000. Finally, Bank of America Corp DE lifted its position in Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock worth $109,452,000 after buying an additional 1,586,230 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of NYSE HLN opened at $9.24 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. Haleon has a twelve month low of $8.65 and a twelve month high of $11.28. The stock has a 50 day moving average of $9.20 and a two-hundred day moving average of $9.87. The stock has a market cap of $40.78 billion, a P/E ratio of 23.68, a P/E/G ratio of 2.06 and a beta of 0.13.

Haleon (NYSE:HLN) last released its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The company had revenue of $3.65 billion during the quarter. On average, research analysts forecast that Haleon will post 0.55 earnings per share for the current year.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.